Vertex Pharmaceuticals Incorporated is a global biotechnology company. Co. is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. We show 58 historical shares outstanding datapoints in our VRTX shares outstanding history coverage, used to compute VRTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VRTX market cap history over the course of time is important for investors
interested in comparing VRTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VRTX versus a peer is one thing; comparing
VRTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VRTX can fluctuate over the course of history.
With this page we aim to empower investors researching VRTX by allowing them to research the VRTX market cap history. |
Free VRTX Email Alerts:
Video: The Importance of Market Cap
